MariTide (Maridebart Cafraglutide)
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is MariTide (Maridebart Cafraglutide)?
Amgen's investigational once-monthly conjugate, maridebart cafraglutide, pairing a GLP-1 agonist with a GIP antagonist.
Phase 2 (NEJM 2025) reported 16–20% weight loss. Its GIP direction is the opposite of tirzepatide's, which is what makes it interesting. Not approved.
GLP-1 pipeline: survodutide, MariTide, ecnoglutide →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where MariTide (Maridebart Cafraglutide) comes up on this site
On GLP Watchdog, MariTide comes up in 2 research articles.
Research that discusses it
Connected terms
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers